Leijen, S., Soetekouw, P. M. M. B., Jeffry Evans, T. R., Nicolson, M., Schellens, J. H. M., Learoyd, M., . . . Middleton, M. (2011). A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Springer-Verlag.
Chicago Style CitationLeijen, Suzanne, et al. A Phase I, Open-label, Randomized Crossover Study to Assess the Effect of Dosing of the MEK 1/2 Inhibitor Selumetinib (AZD6244; ARRY-142866) in the Presence and Absence of Food in Patients With Advanced Solid Tumors. Springer-Verlag, 2011.
MLA CitationLeijen, Suzanne, et al. A Phase I, Open-label, Randomized Crossover Study to Assess the Effect of Dosing of the MEK 1/2 Inhibitor Selumetinib (AZD6244; ARRY-142866) in the Presence and Absence of Food in Patients With Advanced Solid Tumors. Springer-Verlag, 2011.